Patents by Inventor Carey Horchler
Carey Horchler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080318943Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. These novel compounds provide a treatment or prophylaxis of anxiety disorders, schizophrenia, cognitive disorders, and/or mood disorders.Type: ApplicationFiled: June 18, 2008Publication date: December 25, 2008Applicant: ASTRAZENECA ABInventors: Hui-Fang Chang, Marc Chapdelaine, Bruce Thomas Dembofsky, Keith John Herzog, Carey Horchler, Richard Jon Schmiesing
-
Publication number: 20080113983Abstract: Acetylcholine receptor ligands of formula I wherein A, Ar1 and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.Type: ApplicationFiled: December 13, 2005Publication date: May 15, 2008Applicant: AstraZeneca ABInventors: Marc Chapdelaine, Hui-Fang Chang, Keith J. Herzog, Carey Horchler, Eifion Phillips
-
Publication number: 20080076759Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: September 28, 2007Publication date: March 27, 2008Applicant: AstraZeneca ABInventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John McCauley
-
Patent number: 7285662Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: GrantFiled: April 18, 2005Date of Patent: October 23, 2007Assignee: AstraZeneca ABInventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley
-
Publication number: 20060178372Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: April 4, 2006Publication date: August 10, 2006Applicant: AstraZeneca ABInventors: Markus Haeberlein, Daniel Sohn, Marc Chapdelaine, Timothy Davenport, Carey Horchler, Edward Pierson, John McCauley
-
Patent number: 7045514Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: GrantFiled: July 12, 2004Date of Patent: May 16, 2006Assignee: AstraZeneca ABInventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley
-
Patent number: 7026314Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.Type: GrantFiled: January 15, 2002Date of Patent: April 11, 2006Assignee: AstraZeneca ABInventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
-
Publication number: 20060019947Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B in antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.Type: ApplicationFiled: September 16, 2005Publication date: January 26, 2006Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
-
Publication number: 20050182050Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: April 18, 2005Publication date: August 18, 2005Applicant: AstraZeneca ABInventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John McCauley
-
Publication number: 20050096312Abstract: Provided herein is a compound having the formula (I), (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of a heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: November 1, 2002Publication date: May 5, 2005Inventors: Markus Haeberlein, Daniel Sohn, Marc Chapdelaine, Timothy Davenport, Carey Horchler, Edward Pierson, John McCauley
-
Publication number: 20050085457Abstract: Provided herein is a compound having the formula (I) (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of q heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: November 1, 2002Publication date: April 21, 2005Inventors: Markus Haeberlein, Daniel Sohn, Marc Chapdelaine, Timothy Davenport, Carey Horchler, Edward Pierson, John McCauley
-
Publication number: 20050070544Abstract: Compounds are disclosed according to structural diagram (1), wherein R1, A, D and E are as defined in the specification. Also disclosed are methods for the treatment of pain and pharmaceutical compositions comprising a pain-ameliorating effective amount of a compound in accord with structural diagram (1).Type: ApplicationFiled: September 28, 2001Publication date: March 31, 2005Inventors: Megan Murphy, Wenhua Xiao, Dean Brown, Rebecca Urbanek, Frances MClaren, Edward Vacek, Thomas Bare, Carey Horchler, Christine Barlaam, Gary Steelman, Vernon Alford
-
Publication number: 20050009818Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: July 12, 2004Publication date: January 13, 2005Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John McCauley
-
Patent number: 6812225Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: GrantFiled: January 16, 2002Date of Patent: November 2, 2004Assignee: AstraZeneca ABInventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley
-
Publication number: 20040110745Abstract: Provided herein is a compound represented by the Formula (I) wherein said compounds are useful for the treatment of migraine. Also provided are processes for the preparation of compounds of Formula (I) and intermediates.Type: ApplicationFiled: July 16, 2003Publication date: June 10, 2004Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
-
Publication number: 20040087575Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.Type: ApplicationFiled: July 16, 2003Publication date: May 6, 2004Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
-
Publication number: 20040082591Abstract: Provided herein is a compound having the formula (I) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.Type: ApplicationFiled: July 16, 2003Publication date: April 29, 2004Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
-
Publication number: 20030013708Abstract: Provided herein is a compound having the formula (I): 1Type: ApplicationFiled: January 16, 2002Publication date: January 16, 2003Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley